Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Recruiting · NCT06863376 · Interventional (participants receive a specific treatment) · Lead sponsor: Tanta University
View the official record on ClinicalTrials.gov →Interventions studied
Carbocysteine 375 MGPhysical activity, walking, and calorie restriction
What this trial is about
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography
Exclusion criteria
- Pregnant and/or lactating women
- Excessive alcohol use (defined as an average alcohol intake \> 30 g per day in men and \> 20 g per day in women)
- Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis.
- patients suffering from chronic kidney disease, and hyper/hypoparathyroidism
- Hypersensitivity to carbocistiene.
Where it is running
1 location listed.
- Tanta Unuversity - Tanta, Egypt